Hormone replacement therapy safe, may be beneficial for women treated for ovarian cancer
the ONA take:
Women with epithelial ovarian cancer, the most common type, can safely take hormone replacement therapy (HRT); furthermore, HRT can have a beneficial effect on their survival, according to a 24-year, phase III international trial.
Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust led the trial, which is the largest trial to investigate HRT’s effects on ovarian cancer survival.
The trial was set up in 1990 and followed 150 women with epithelial ovarian cancer. Half of the women were allocated to receive HRT during their treatment for up to 5 years, and half did not receive HRT. Overall survival in the two groups was compared at a point in 2012, 22 years after the trial began.
In the HRT arm of the trial, 53 of the 75 women (71%) had died, compared with 68 of the 75 women (91%) who had not taken HRT.
The researchers report these results are relevant to a large proportion of women with ovarian cancer because its treatment can trigger menopause.
“We were really happy to be able to show that HRT is safe for women with the most common type of ovarian cancer. Whether or not to have HRT is a very important decision for a large proportion of women with ovarian cancer, who will often have to undergo the menopause due to the cancer treatment at the same time as coping with a cancer diagnosis,” said study clinical lead Professor Ros Eeles, professor of Oncogenetics at The Institute of Cancer Research, London, and consultant at The Royal Marsden NHS Foundation Trust.
Women with epithelial ovarian cancer, the most common type, can safely take hormone replacement therapy.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|